ArticleWorld journal of experimental medicine2025
Efficacy of beta-blockers in the treatment of hematidrosis: A systematic review.
Article in World journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematidrosis is an extremely rare and enigmatic condition characterized by spontaneous bleeding through intact skin or mucosa, typically occurring in response to severe emotional stress. Although its exact pathophysiology remains unclear, the condition is thought to involve sympathetic nervous system overactivation and capillary fragility, leading to blood extravasation
aimTo evaluate the efficacy and safety of beta-blockers, particularly propranolol, in the management of hematidrosis.
methodsA systematic literature search was conducted in January 2024 across six major databases to identify studies published between 2014 and 2024 that reported the use of beta-blockers in patients with hematidrosis. Eligible studies included clinical case reports or case series that described beta-blocker treatment outcomes. Data were synthesized narratively in accordance with the PRISMA 2020 guidelines.
resultsTwenty studies met the inclusion criteria. Among them, propranolol was the most frequently prescribed beta-blocker and was associated with symptomatic improvement in over 75% of cases. Some studies also reported enhanced outcomes when beta-blockers were used in conjunction with psychotherapy. Reported adverse effects were minimal, and treatment was generally well-tolerated. However, the available evidence remains limited to low-level observational data, mostly case reports and small case series.
conclusionBeta-blockers, especially propranolol, appear to be an effective and well-tolerated treatment option for hematidrosis, particularly in stress-induced presentations. Despite promising findings, the evidence base is constrained by the lack of high-quality studies. Future research should focus on prospective, controlled trials to establish standardized diagnostic and treatment protocols for this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.